AstraZeneca 
Welcome,         Profile    Billing    Logout  
 352 Products   698 Diseases  352 Products   2537 Trials   126029 News 
3692 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
brazikumab (AMG 139) / AstraZeneca
INTREPID OLE, NCT03961815 / 2019-001866-14: Open-label Extension Study of Brazikumab in Crohn's Disease

Jan 2024 - Dec 2024: Data from trial for Crohn's disease
Terminated
3
18
Europe, US, RoW
Brazikumab Induction Dose, Brazikumab Maintenance Dose
AstraZeneca
Crohn's Disease, IBD
09/23
09/23
INTREPID, NCT03759288 / 2018-004346-42: An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

Jan 2024 - Dec 2024: Data from INTREPID trial for Crohn’s disease
Checkmark Trial initiation for Crohn’s disease
Nov 2018 - Nov 2018: Trial initiation for Crohn’s disease
Terminated
2/3
89
Europe, Canada, US, RoW
Brazikumab low dose, Brazikumab high dose, Humira®, Placebo
AstraZeneca
Crohn's Disease, IBD
10/23
10/23
Expedition, NCT04718818: An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
225
Europe, Canada, US, RoW
Brazikumab, Vedolizumab, Placebo
AstraZeneca
Ulcerative Colitis
07/22
09/23
NCT04277546 / 2021-001644-10: Open-label Extension Study of Brazikumab in Ulcerative Colitis

Jan 2024 - Dec 2024: Data from trial for ulcerative colitis
Terminated
2
57
Europe, Japan, US, RoW
Brazikumab Maintenance Dose, Brazikumab Induction Dose
AstraZeneca
Ulcerative Colitis
10/23
10/23
NCT03616821 / 2018-001605-93: Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

Jan 2024 - Dec 2024: Data from EXPEDITION trial for ulcerative colitis
Checkmark Initiation of trial
Aug 2018 - Aug 2018: Initiation of trial
Terminated
2
242
Europe, Canada, Japan, US, RoW
Brazikumab, Placebo
AstraZeneca
Ulcerative Colitis, IBD
10/23
10/23
Xigduo (dapagliflozin and metformin extended-release) / AstraZeneca
NCT02911792: Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

Completed
4
72
US
Dapagliflozin, Farxiga, Metformin, Metformin-XR, Glipizide 5 MG
The University of Texas Health Science Center at San Antonio, AstraZeneca
Diabetes Mellitus, Type 2
07/23
07/23
NCT03710460: Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

Recruiting
4
33
RoW
Dapagliflozin, Forxiga, Dapagliflozin plus Metformin XR, XigDuo, Metformin XR
University of Guadalajara
Obesity
12/23
12/23
NCT06327815: Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Active, not recruiting
4
632
RoW
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, FDC Regimen of Dapagliflozin/Metformin XR, Dapagliflozin tablets and Metformin HCl extended-release tablets, Co-administered Dual Therapy
AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
04/25
06/25
NCT05601336: of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

Recruiting
3
200
RoW
Dapagliflozin 5 MG, [Farxiga], Metformin Hydrochloride 1000 MG, Glucophage 1000mg, Dapagliflozin/Metformin, Xigduo
Beni-Suef University
PCO
07/23
07/23
NCT06405178: Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Not yet recruiting
3
500
RoW
Metformin, Glucophage 1000, Dapagliflozin, Forxiga, Dapagliflozin/Metformin, Xigduo, Letrozole, femara
Beni-Suef University
Polycystic Ovary
12/24
12/24
NCT07026968: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Not yet recruiting
3
815
NA
Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
CSPC Ouyi Pharmaceutical Co., Ltd.
Type 2 Diabetes
10/26
11/26
EPIK-B4, NCT04899349: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Terminated
2
2
US, RoW
Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin
Novartis Pharmaceuticals
Breast Cancer
05/23
05/23
SOLDMiDiab02, NCT05477017: Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Not yet recruiting
N/A
800
Europe
SGLT2 inhibitor, Jardiance, Synjardy, Forxiga, Xigduo, Invokana, Vokanamet, Steglatro, Segluromet
University of Milan
Type2Diabetes
12/22
03/23
Imjudo (tremelimumab-actl) / AstraZeneca
2019-002767-98: A study of immunotherapy combined with regular treatment for liver cancer

Not yet recruiting
4
13
Europe
IMFINZI, Tremelimumab, Concentrate for solution for infusion, Solution for infusion, IMFINZI
University College Dublin, AstraZeneca
Patients with Hepatocellular Carcinoma, Liver Cancer, Diseases [C] - Cancer [C04]
 
 
ARCTIC, NCT02352948 / 2014-000338-46: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Not Appicable Jan 2018 - Jun 2018 : Acceptance of regulatory submission of durvalumab + tremelimumab based on ARCTIC trial for 3L NSCLC (P3 trial failed)
Not Appicable Jan 2018 - Jun 2018 : Acceptance of regulatory submission of durvalumab + tremelimumab based on ARCTIC trial for 3L NSCLC (P3 trial failed)
Not Appicable Jan 2018 - Jun 2018 : Regulatory submission of durvalumab + tremelimumab based on ARCTIC trial for 3L NSCLC (P3 trial failed)
Checkmark ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
Apr 2018 - Apr 2018: ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
More
Completed
3
597
Europe, Canada, Japan, US, RoW
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
AstraZeneca
Non - Small Cell Lung Cancer NSCLC
02/18
08/23
MYSTIC, NCT02453282 / 2015-001279-39: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Not Appicable Jan 2020 - Dec 2020 : Submission in China for durvalumab + tremelimumab combination in 1L NSCLC (based on MYSTIC trial) (P3 trial failed)
Checkmark From MYSTIC trial in 1L mNSCLC
Apr 2020 - Apr 2020: From MYSTIC trial in 1L mNSCLC
Checkmark Results for metastatic NSCLC [MYSTIC]
Dec 2018 - Dec 2018: Results for metastatic NSCLC [MYSTIC]
More
Active, not recruiting
3
1118
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
10/18
12/25
DANUBE , NCT02516241 / 2015-001633-24: Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Checkmark Withdrawal of advanced bladder cancer indication in the US
Feb 2021 - Feb 2021: Withdrawal of advanced bladder cancer indication in the US
Checkmark From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Sep 2020 - Sep 2020: From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Checkmark From DANUBE trial in combination with durvalumab vs chemo in Stage IV urothelial cancer
More
Active, not recruiting
3
1126
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine
AstraZeneca
Urothelial Cancer
01/20
12/25
CASPIAN, NCT03043872 / 2016-001203-23: Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer

Checkmark From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Sep 2021 - Sep 2021: From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Checkmark Approved in China for 1L ES-SCLC (based on CASPIAN Phase III trial)
Jul 2021 - Jul 2021: Approved in China for 1L ES-SCLC (based on CASPIAN Phase III trial)
Checkmark Approved in European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in 2L NSCLC
More
Active, not recruiting
3
987
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
01/20
12/25
NEPTUNE, NCT02542293 / 2015-002197-21: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC)

Not Appicable Jan 2020 - Dec 2020 : Submission for 1L NSCLC (based on NEPTUNE trial) in China (endpoint not met)
Checkmark From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Aug 2019 - Aug 2019: From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Active, not recruiting
3
953
Europe, Japan, US, RoW
Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
09/20
12/25
POSEIDON, NCT03164616 / 2017-000920-81: Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer ().

Checkmark Approved in combination with Imjudo + chemotherapy for treatment of unresectable, advanced/recurrent NSCLC based on POSEIDON trial
Dec 2022 - Dec 2022: Approved in combination with Imjudo + chemotherapy for treatment of unresectable, advanced/recurrent NSCLC based on POSEIDON trial
Checkmark Approved in EU in combination with tremelimumab 1L NSCLC cancer based on POSEIDON trial
Dec 2022 - Dec 2022: Approved in EU in combination with tremelimumab 1L NSCLC cancer based on POSEIDON trial
Checkmark Approved in US combination with tremelimumab for 1L NSCLC (based on POSEIDON trial)
More
Active, not recruiting
3
1186
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
AstraZeneca
Non Small Cell Lung Cancer NSCLC
03/21
11/27
HIMALAYA, NCT03298451 / 2016-005126-11: Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Hourglass Jan 2024 - Dec 2024 : Submission in China for 1L HCC (based on HIMALAYA trial)
Hourglass Jan 2023 - Dec 2023 : Regulatory decision in EU in combination with Imfinzi for 1L HCC (based on HIMALAYA trial)
Checkmark From HIMALAYA trial in combination with tremelimumab for 1L unresectable HCC at ASCO-GI 2023
Jan 2023 - Jan 2023: From HIMALAYA trial in combination with tremelimumab for 1L unresectable HCC at ASCO-GI 2023
Checkmark Approved in combination with Imjudo for unresectable HCC based on HIMALAYA trial
More
Active, not recruiting
3
1324
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)
AstraZeneca
Hepatocellular Carcinoma
08/21
08/26
2020-005452-38: Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse Cisplatin

Not yet recruiting
3
830
Europe
Durvalumab, Tremelimumab, Enfortumab vedotin, MEDI4736, EV, Concentrate for solution for infusion, Powder for solution for infusion, IMFINZI, Padcev
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Documented muscle-invasive urothelial carcinoma (UC) of the bladder incisplatin ineligible patients or Who Refuse Cisplatin, Cancer in thick muscle in the bladder wall, Diseases [C] - Cancer [C04]
 
 
NILE, NCT03682068 / 2018-001883-48: Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Hourglass Jul 2023 - Dec 2023 : Data from NILE trial in combination with tremelimumab for 1L bladder cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission (based on NILE trial) in combination with Imfinzi for urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission based on NILE trial in EU in combination with tremelimumab for 1L urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU in combination with Imfinzi for 1L urothelial cancer (based on NILE trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan in combination with tremelimumab for 1L urothelial cancer based on NILE trial
More
Active, not recruiting
3
1246
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine
AstraZeneca
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
06/25
06/25
NCT04585490: Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Recruiting
3
48
US
Durvalumab, Imfinzi, MEDI-4736, MEDI4736, Carboplatin, Carboplat, Carbosol, Carboplatino, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum, Pemetrexed, Alimta, MTA, LY231514, L-glutamic acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), Paclitaxel, Praxel, Cisplatin, platinum diamminodichloride, Abiplatin, Cismaplat, cis-platinum, Platinex, platinum, diaminedichloro-, cis- (8CI), AVENIO ctDNA Surveillance Kit, Tremelimumab, Imjudo, Tremelimumab-actl, Ticilimumab, CP-675, CP-675,206
Maximilian Diehn, AstraZeneca
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
04/26
04/28
RAMPART, NCT03288532 / 2017-002329-39: Renal Adjuvant MultiPle Arm Randomised Trial

Hourglass Oct 2023 - Dec 2023 : From RAMPART trial with or without in combination with tremelimumab
Recruiting
3
1750
Europe
Durvalumab, Tremelimumab
University College, London, AstraZeneca, Kidney Cancer UK, Cancer Research UK
Renal Cell Carcinoma
07/24
12/34
ADRIATIC, NCT03703297 / 2018-000867-10: Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Hourglass Jan 2024 - Dec 2024 : Regulatory submission for 1L SCLC
Hourglass Jan 2024 - Dec 2024 : Regulatory submission for SCLC
Jul 2023 - Dec 2023: Acceptance of regulatory submission in combination with tremelimumab for SCLC cancer (based on ADRIATIC trial)
Jan 2023 - Jun 2023: Data from ADRIATIC trial in combination with tremelimumab for stage I-III SCLC
Active, not recruiting
3
730
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Placebo
AstraZeneca
Small Cell Lung Cancer
03/26
03/26
TREMENDOUS, NCT05557838: Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Recruiting
3
210
RoW
Durvalumab, MEDI4736, Tremelimumab
AstraZeneca
Hepatocellular Carcinoma
03/25
03/25
ARTEMIDE-HCC01, NCT06921785: Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Recruiting
3
1220
Europe, Canada, Japan, US, RoW
Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab
AstraZeneca
Hepatocellular Carcinoma
03/29
03/30
SIERRA, NCT05883644: Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting
3
111
Europe, Japan, US, RoW
Durvalumab, Tremelimumab
AstraZeneca
Advanced Hepatocellular Carcinoma
09/25
03/26
DARTS, NCT07027436: Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

Not yet recruiting
3
30
Canada
Chemotherapy/Radiation, Group 1
Hamilton Health Sciences Corporation, McMaster University
Hepatocellular Carcinoma (HCC)
10/27
10/28
VOLGA, NCT04960709 / 2020-005452-38: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with tremelimumab and Padcev for MIBC (based on VOLGA trial)
Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Padcev and Imfinzi for MIBC (based on VOLGA trial)
Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi and tremelimumab for MIBC (based on VOLGA trial)
Jan 2024 - Dec 2024: Data from VOLGA trial in combination with tremelimumab and Padcev for MIBC
Active, not recruiting
3
712
Europe, Canada, Japan, US, RoW
Durvalumab, IMFINZI, MEDI4736, Tremelimumab, Enfortumab Vedotin, PADCEV, Radical Cystectomy
AstraZeneca, AstraZeneca AB
Muscle Invasive Bladder Cancer
07/25
09/28
EMERALD-3, NCT05301842 / 2021-003822-54: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with tremelimumab for HCC (based on EMERALD-3 trial)
Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi for HCC (based on EMERALD-3 trial)
Jan 2024 - Dec 2024: Data from EMERALD-3 trial in combination with tremelimumab for HCC
Active, not recruiting
3
760
Europe, Canada, Japan, US, RoW
Tremelimumab, MEDI1123, Durvalumab, MEDI4736, Transarterial Chemoembolization (TACE), DEB-TACE and cTACE, Lenvatinib, Lenvima
AstraZeneca
Hepatocellular Carcinoma
12/25
02/27
TRITON, NCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Recruiting
3
280
US
Durvalumab, MEDI4736 & IMFINZI®, Tremelimumab, IMJUDO®, Pemetrexed, Background Platinum-based Chemotherapy, Pembrolizumab, Carboplatin, Cisplatin
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/27
03/31
ALICE, NCT06904170: Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

Not yet recruiting
2/3
196
Europe
Durvalumab Plus Tremelimumab, HAIC (GEMOX)
UNICANCER, AstraZeneca
Hepatocellular Carcinoma
09/29
09/30
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Active, not recruiting
2/3
660
Europe, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
AbbVie
Hepatocellular Carcinoma
09/30
09/30
2015-001995-23: A SINGLE ARM, PHASE II CLINICAL STUDY OF TREMELIMUMAB COMBINED WITH THE ANTI-PD-L1 MEDI4736 MONOCLONAL ANTIBODY IN UNRESECTABLE MALIGNANT MESOTHELIOMA SUBJECTS: NIBIT-MESO-1 STUDY STUDIO CLINICO DI FASE II, A SINGOLO BRACCIO DI TRATTAMENTO CON LA COMBINAZIONE TREMELIMUMAB E L’ANTICORPO MONOCLONALE ANTI-PD-L1 MEDI4736 A IN SOGGETTII CON MESOTELIOMA MALIGNO NON RESECABILE

Not yet recruiting
2
40
Europe
Tremelimumab, MEDI4736, Solution for infusion
FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI, Astra Zeneca
UNRESECTABLE MALIGNANT MESOTHELIOMA MESOTELIOMA MALIGNO NON RESECABILE, UNRESECTABLE MALIGNANT MESOTHELIOMA MESOTELIOMA MALIGNO NON RESECABILE, Diseases [C] - Cancer [C04]
 
 
DETERMINE, NCT01843374 / 2012-003524-21: Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Checkmark From DETERMINE trial in 2nd-line malignant mesothelioma
Jul 2017 - Jul 2017: From DETERMINE trial in 2nd-line malignant mesothelioma
Hourglass Jul 2016 - Dec 2016 : Regulatory submission for mesothelioma
Checkmark Completion of enrollment in P2 trial for malignant mesothelioma
Nov 2016 - Nov 2016: Completion of enrollment in P2 trial for malignant mesothelioma
More
Active, not recruiting
2
571
Europe, Canada, US, RoW
Tremelimumab, Placebo
MedImmune LLC
Unresectable Pleural or Peritoneal Malignant Mesothelioma
01/16
04/25
2005-005660-86: A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal Adenocarcinoma

Ongoing
2
Europe
Ticilimumab, CP-675, 206,
Christie Hospital NHS Trust
Advanced Gastric/Oesophageal Adenocarcinoma
 
 
2016-001688-35: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors Studio in aperto, randomizzato, di fase 2 con l¿anticorpo anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, da solo o in combinazione con Tremelimumab, in pazienti con neoplasie germinali avanzate e ricadute alla chemioterapia

Ongoing
2
120
Europe
MEDI4736, Tremelimumab, MEDI4736, MEDI1123, Solution for infusion, Concentrate for solution for infusion
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Astra Zeneca
Advanced and relapsed germ cell tumors Neoplasie germinali in fase metastatica ricadute o in progressione dopo trattamento chemioterapico di seconda o terza linea., Germ cell Tumor Neoplasie germinali in fase metastatica ricadute o in progressione dopo trattamento chemioterapico di seconda o terza linea., Diseases [C] - Cancer [C04]
 
 
ESR-16-12012, NCT06446570: Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Completed
2
18
RoW
Durvalumab,Tremelimumab, Experimental group
Seoul National University Hospital, Korean Cancer Study Group
HNSCC, Head and Neck Neoplasms
02/19
06/21
NCT02527434 / 2015-002934-32: Study of Tremelimumab in Patients With Advanced Solid Tumors

Hourglass Nov 2018 - Dec 2018 : In urothelial bladder cancer, TNBC and pancreatic ductal adneocarcinoma
Completed
2
64
Europe, US, RoW
Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy
AstraZeneca
Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
02/18
03/23
2017-001664-37: A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC Studio randomizzato di fase 2 di confronto tra immunoterapia e chemioterapia nel trattamento del paziente anziano

Ongoing
2
240
Europe
CARBOPLATINO, Durvalumab, Tremelimumab, Gemcitabina, Pemetrexed, [CARBOPLATINO], [Durvalumab], [Tremelimumab], [Gemcitabina], [Pemetrexed], Concentrate for solution for infusion, Solution for infusion, CARBOPLATINO SANDOZ GMBH - 10MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 60ML, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 15 ML, ALIMTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A.
patients with advanced NSCLC pazienti con NSCLC avanzato, patients with advanced non-small cell lung cancer pazienti con tumore del polmone non a piccole cellule avanzato, Diseases [C] - Cancer [C04]
 
 
2017-004213-24: A RANDOMIZED TRIAL OF DURVALUMAB AND TREMELIMUMAB ¿ PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK, METASTATIC (STAGE IV) SQUAMOUS OR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) Studio randomizzato di Duravalumab e Tremelimumab ¿ Chemioterapia a base di platino in pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso

Not yet recruiting
2
300
Europe
Durvalumab, Tremelimumab, Gemcitabina, CARBOPLATINO, Pemetrexed, Durvalumab, Tremelimumab, Gemcitabina, CARBOPLATINO, Pemetrexed, Solution for infusion, Concentrate for solution for infusion, GEMCITABINA ACCORD HEALTHCARE - 1 G POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 50 ML, CARBOPLATINO AHCL - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 45 ML, ALIMTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, Canadian Cancer Trials Group (CCTG)
Patients with high-risk, metastatic (Stage IV) squamous or non-squamous NSCLC. Pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso., Patients with high-risk, metastatic (Stage IV) squamous or non-squamous NSCLC. Pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso., Diseases [C] - Cancer [C04]
 
 
2016-003175-22: Trial with immunotherapie for patients with locally advanced head and neck cancer Studie zur Immuntherapie bei Patienten mit lokal fortgeschrittenen Tumoren des Kopf-Hals Bereichs

Ongoing
2
120
Europe
Durvalumab, Tremelimumab, MEDI4736, Solution for infusion
Charite Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, AstraZeneca GmbH
NON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCC, locally advanced head and neck cancer Fortgeschrittene Kopf-Hals Tumoren, Diseases [C] - Cancer [C04]
 
 
2017-000577-36: DUTRELASCO trial (DUrvalumab with or without Tremelimumab in REsectable Locally Advanced Squamous cell Carcinoma of the Oral cavity)

Not yet recruiting
2
20
Europe
Tremelimumab, Durvalumab (Medi 4736), Medi 4736, Solution for infusion, Durvalumab (Medi 4736)
University Hospitals Leuven, University Hospitals Leuven, Astra Zeneca
resectable, locally advanced squamous cell carcinoma of the oral cavity, resectable, locally advanced squamous cell carcinoma of the oral cavity, Diseases [C] - Cancer [C04]
 
 
2017-003226-33: Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

Ongoing
2
120
Europe
Durvalumab, Tremelimumab, MEDI4736, MEDI1 123, Concentrate for solution for infusion
Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Jürgen Schüttler, Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg
Locally advanced head and neck squamous cell carcinoma (HNSCC), Head and neck cancer, Diseases [C] - Cancer [C04]
 
 
2017-003159-44: Durvalumab plus tremelimumab and radiotherapy for localized muscle invasivebladder cancer treatment Durvalumab más tremelimumab y radioterapia concomitante para el tratamiento del carcinoma de vejiga músculo-invasivo localizado

Ongoing
2
32
Europe
Durvalumab, Tremelimumab, MEDI4736, Tremelimumab, Solution for infusion
Spanish Oncology Genitourinary Group, AstraZeneca
Localized muscle invasive bladder cancer Carcinoma de vejiga músculo-invasivo localizado, Invasive bladder cancer Cáncer invasivo de vejiga, Diseases [C] - Cancer [C04]
 
 
ACTRN12617001468314: Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
2
80
 
NHMRC Clinical Trials Centre, Canadian Cancer Trials Group
Lung Cancer Metastatic
 
 
2018-002014-13: Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancer Évaluation de l'efficacité d'un traitement combiné immunothérapie + chimiothérapie pour traiter les patients atteints d'un cancer de l'estomac.

Not yet recruiting
2
94
Europe
MEDI4736, tremelimumab, MEDI4736, MEDI1123, Concentrate for solution for infusion
Fédération Francophone de Cancérologie Digestive, Astra Zeneca
Advanced gastric or gastro-oesophageal junction adenocarcinoma Adénocarcinome gastrique ou de la jonction oeso-gastrique avancé, Advanced gastric or gastro-oesophageal junction adenocarcinoma Adénocarcinome gastrique ou de la jonction oeso-gastrique avancé, Diseases [C] - Cancer [C04]
 
 
2018-003115-21: A phase II trIal for combination therapy with durvaLumab anD tremelimumAb in patients with metastatic solid tumors

Not yet recruiting
2
108
Europe
durvalumab, Tremelimumab, MEDI4736, Solution for infusion
Gustave Roussy, AstraZeneca
Metastatic colorectal adenocarcinoma (without microsatellite instability (not MSI)), triple negative breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma and human papilloma virus (HPV) negative head and neck squamous cell carcinoma with detection of ≥ 5 somatic mutations per megabase measured by whole exome sequencing in a tumor sample of the patient, Metastatic colorectal adenocarcinoma, breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma and HPV negative head and neck squamous cell carcinoma, Diseases [C] - Cancer [C04]
 
 
2017-003780-35: Phase II Study: Second line therapy in patients with non small cell lung cancer (NSCLC) with Durvalumab plus Tremelimumab after platinum based chemotherapie compared with platinum based chemotherapy alone Phase II Studie: Zweitlinientherapie in Patienten mit nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Durvalumab plus Tremelimumab nach Platinum-basierter Chemotherapie verglichen mit alleiniger Platinum-basierter Chemotherapie

Not yet recruiting
2
196
Europe
Durvalumab, Tremelimumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Gemcitabine, MEDI4736, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for infusion
AIO-Studien-gGmbH, AstraZeneca GmbH
Non-small cell lung cancer stage IV Nicht-kleinzelliges Bronchialkarzinom Stadium IV, Lungcancer Lungenkrebs, Diseases [C] - Cancer [C04]
 
 
2018-002971-17: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after Olaparib treatment Evaluation de l'efficacité d’une double immunothérapie par Durvalumab et Tremelimumab associée à un traitement par Olaparib chez des patients atteints d’un cancer solide porteurs d’une mutation d’un gène de la recombinaison homologue, en réponse ou stables après 8 semaines de traitement par Olaparib.

Not yet recruiting
2
270
Europe
OLAPARIB, DURVALUMAB, TREMELIMUMAB, AZD2281, MEDI4736, MEDI1123, Coated tablet, Concentrate for solution for infusion, Lynparza 100 mg film-coated Tablet
Centre Georges-François Leclerc, AstraZeneca, Centre Georges-François Leclerc
Patients with the following solid malignancy: • Metastatic breast cancer • Metastatic prostate cancer • Metastatic lung cancer • Metastatic head and neck • Metastatic endometrial cancer • Metastatic clear cell renal cancer • Metastatic pancreatic cancer • Metastatic ovarian cancer • Metastatic urothelial carcinoma Patients atteints d’une tumeur maligne parmi les suivantes : - Cancer du sein métastatique - Cancer de la prostate métastatique - Cancer du poumon métastatique - Cancer de l’endomètre métastatique - Cancer rénal à cellules claires métastatique - Cancer de la tête et du coup (ORL) métastatique - Cancer du pancréas métastatique - Cancer de l’ovaire localement avancé ou métastatique - Carcinome urothélial métastatique, Patient with the following metastatic solid malignancy of breast , prostate , lung , head and neck, endometrial, clear cell renal, pancreatic, ovarian or urothelial . Patient atteint d’une tumeur maligne métastatique du sein, de la prostate, du poumon, de l’endomètre, rénal à cellules claires, de la tête et du coup (ORL), du pancréas, de l’ovaire ou urothéliale., Diseases [C] - Cancer [C04]
 
 
2019-000308-13: Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virus

Not yet recruiting
2
180
Europe
Durvalumab, Cisplatin, MEDI4736, Concentrate for solution for infusion
European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Canadian Cancer Trials Group (CCTG), AstraZeneca
Oropharyngeal Squamous Cell Carcinoma, Cancer of the Head and Neck, Diseases [C] - Cancer [C04]
 
 
2018-004778-81: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Not yet recruiting
2
50
Europe
Durvalumab, Tremelimumab, Solution for infusion, IMFINZI
Institut für Klinische Krebsforschung IKF GmbH, AstraZeneca GmbH, BTG International Ltd.
Intrahepatic Biliary Tract Carcinoma, Intrahepatic Biliary Tract Cancer, Diseases [C] - Cancer [C04]
 
 
ACTRN12616001019493: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum: durvalumab plus tremelimumab

Completed
2
112
 
University of Sydney, Office for Health and Medical Research
Cancer
 
 
DUNE, NCT03095274 / 2016-002858-20: Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Completed
2
126
Europe
Durvalumab, MEDI4736, Tremelimumab, CP-675,206
Grupo Espanol de Tumores Neuroendocrinos
Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung
11/19
05/22
2018-002852-34: Durvalumab and Tremelimumab with microwave tumor ablation for unresectable locally advanced pancreatic cancer.

Not yet recruiting
2
20
Europe
Tremelimumab, Durvalumab (Medi4736), MEDI1123, MEDI4736, Solution for infusion, Durvalumab
UZLeuven, AstraZeneca
Unresectable Locally Advanced Non Metastatic Pancreatic Cancer, Pancreatic Cancer, Diseases [C] - Cancer [C04]
 
 
2018-001066-42: Durvalumab plus tremelimumab for progressive, refractory advanced thyroid carcinoma Durvalumab más tremelimumab para el carcinoma tiroideo avanzado, resistente al tratamiento y progresivo

Not yet recruiting
2
84
Europe
Durvalumab, Tremelimumab, MEDI4736, Tremelimumab, Solution for infusion, IMFINZI
Spanish Group of Neuroendocrine Tumors (GETNE), AstraZeneca
Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary,follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC).Advanced medullary thyroid carcinoma (MTC)Advanced anaplastic thyroid cancer (ATC) Carcinoma de tiroides diferenciado, avanzado, refractario al yodo radiactivo, incluyendo carcinoma tiroideo papilar, folicular, de células de Hürthle y poco diferenciado (CDT).Carcinoma medular de tiroides (CMT) avanzado.Cáncer anaplásico de tiroides (CAT) avanzado., Thyroid cancer Cáncer de tiroides, Diseases [C] - Cancer [C04]
 
 
CCTG BR34, NCT03057106 / ACTRN12617001468314: Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Active, not recruiting
2
301
Canada, RoW
Durvalumab, Tremelimumab, Platinum-Based Drug
Canadian Cancer Trials Group, AstraZeneca, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, National Health and Medical Research Council, Australia
Lung Cancer Metastatic
02/20
06/25
NCT03046862: Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Active, not recruiting
2
31
RoW
Durvalumab, MEDI4736, Tremelimumab, Gemcitabine, Cisplatin
Seoul National University Hospital
Biliary Tract Neoplasms
05/20
12/24
2018-003048-22: A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition Eine Phase II Studie zur Evaluation der Sicherheit und Wirksamkeit von Durvalumab in Kombination mit der standard neoadjuvanten Therapie sowie zur Evaluation von Durvalumab +/- Tremelimumab bei Patienten mit lokal fortgeschrittenem Adenokarzinom des Ösophagus und zusätzlich Evaluation von Biomarkern, die eine Ansprechen auf Immuncheckpoint Inhibitoren vorhersagen könnten

Not yet recruiting
2
56
Europe
Durvalumab, Tremelimumab, Solution for injection, Imfinzi®
Universität zu Köln, AstraZeneca Ab
locally advanced esophageal adenocarcinoma lokal fortgeschrittenes Adenokarzinom des Ösophagus, cancer of the esophagus lokal fortgeschrittenes Adenokarzinom der Speiseröhre, Diseases [C] - Cancer [C04]
 
 
BALTIC, NCT02937818 / 2016-001202-42: A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Checkmark Results in combination with tremelimumab for refractory/resistant ES-SCLC from BALTIC trial
Mar 2022 - Mar 2022: Results in combination with tremelimumab for refractory/resistant ES-SCLC from BALTIC trial
Completed
2
72
Europe, RoW
Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib
AstraZeneca
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
06/20
11/23
CCTG PA.7, NCT02879318: Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Completed
2
180
Canada
Gemcitabine, Nab-paclitaxel, Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Pancreatic Adenocarcinoma
08/20
03/25
2019-004597-26: A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT for intermediate stage HCC - IMMUWIN Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit Y-90 SIRT bei Patienten mit Leberzellkarzinom im Zwischenstadium - IMMUWIN

Not yet recruiting
2
54
Europe
Durvalumab, Tremelimumab, Solution for infusion, IMFINZI
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH
Intermediate stage hepatocellular carcinoma (HCC), Intermediate stage hepatocellular carcinoma (HCC), Diseases [C] - Cancer [C04]
 
 
SOGUG, NCT03702179 / 2017-003159-44: Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

Completed
2
32
Europe
Durvalumab, MEDI4736, Tremelimumab, Radiotherapy
Spanish Oncology Genito-Urinary Group, AstraZeneca, MFAR
Invasive Bladder Cancer
09/20
08/22
STUDY 22, NCT02519348 / 2015-001663-39: A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Checkmark From STUDY 22 trial in combination with tremelimumab at ASCO 2020
May 2020 - May 2020: From STUDY 22 trial in combination with tremelimumab at ASCO 2020
Active, not recruiting
2
433
Europe, Japan, US, RoW
Tremelimumab, Durvalumab, MEDI4736, Bevacizumab
MedImmune LLC
Hepatocellular Carcinoma
11/20
03/25
2020-003440-92: Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability. Studio con la combinazione di due farmaci immunoterapici come terapia prima della chirurgia o come terapia definitiva in pazienti con tumore gastrico o della giunzione gastro-esofagea operabile con instabilità dei microsatelliti.

Not yet recruiting
2
31
Europe
Durvalumab, Tremelimumab, [MEDI4736], [MEDI1123], Concentrate for solution for infusion
G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST, Fondazione GONO, AstraZeneca S.p.A.
The disease under clinical investigation is represented by resectable gastric or gastroesophageal junction (Siewert II-III) adenocarcinoma staged as cT = 2, any cN, or any cT, cN1-3 (TNM classification 8th edition), without distant metastases (cM0).The study requires central confirmation of tumor molecular status of microsatellite instability and dMMR by both immunohistochemistry and multiplex polymerase chain reaction, and EBV-negative status by silver-in situ hybridization. La malattia oggetto di studio clinico è costituita dall'adenocarcinoma gastrico o della giunzione gastroesofagea (Siewert II-III) resecabile, stadiato clinicamente secondo la classificazione TNM (8° edizione) come cT = 2, ogni cN, oppure ogni cT, cN1-3, senza evidenza di metastasi a distanza (cM0). E' necessaria conferma centralizzata di instabilità microsatellitare mediante immunoistochimica e reazione polimerasica a catena, e status EBV-negativo mediante ibridizzazione in situ argentica., Cancer in the stomach or in the junction between the stomach and the oesophagus, without metastases in other organs and surgically resectable, with microsatellite instability and no EBV infection. Tumore nello stomaco o nella giunzione tra stomaco ed esofago, senza metastasi in altri organi e asportabile chirurgicamente, con instabilità dei microsatelliti e assenza di infezione da EBV., Diseases [C] - Cancer [C04]
 
 
16-C-0135, NCT02821754: A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Completed
2
54
US
Durvalumab, Imfinzi, Tremelimumab, Ticilimumab, Trans-arterial Catheter Chemoembolization (TACE), TACE, Radiofrequency Ablation (RFA), RFA, Cryoablation, Cryosurgery
National Cancer Institute (NCI)
Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
02/21
12/22
DUTRENEO, NCT03472274 / 2017-002246-68: Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients

Completed
2
101
Europe
Durvalumab, Tremelimumab, Cisplatin-based neoadjuvant chemotherapy, Standard of care (SoC)
Fundacion CRIS de Investigación para Vencer el Cáncer, AstraZeneca, Apices Soluciones S.L.
Bladder Cancer
04/21
04/23
NCT03377400: Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Active, not recruiting
2
40
RoW
Durvalumab, tremelimumab, 5FU, Cisplatin
Samsung Medical Center
Esophageal Squamous Cell Carcinoma
06/21
12/21
NCT03450967: Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Active, not recruiting
2
31
RoW
Durvalumab Plus Tremelimumab
Samsung Medical Center
Head and Neck Squamous Cell Carcinoma
06/21
03/22
ACTRN12618000109202: A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers “iPRIME”.

Completed
2
75
 
Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Ovarian cancer, Fallopian tube cancer, Peritoneal cancer
 
 
NRG-GY021, NCT04034927: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Active, not recruiting
2
61
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Ticilimumab, Tremelimumab-actl
National Cancer Institute (NCI), NRG Oncology
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
07/21
02/26
NCT02953457: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Completed
2
40
US
Durvalumab, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Olaparib, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
Roswell Park Cancer Institute, AstraZeneca
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
09/21
08/24
CheckRad-CD8, NCT03426657: Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

Completed
2
120
Europe
Durvalumab + Tremelimumab + RT
University of Erlangen-Nürnberg Medical School
Locally Advanced Head and Neck Squamous Cell Carcinoma
09/21
02/24
2020-003925-42: Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer

Not yet recruiting
2
84
Europe
Tremelimumab, Durvalumab, TheraSphere, Solution for infusion, Implant, TheraSphere
Clinics of Munich University LMU, Astra Zeneca, Boston Scientific
Patients with hepatocellular cancer, not amenable to curative surgical or ablation treatment., tumor of the liver which cannot be removed by surgery or other ablation techniques, Diseases [C] - Cancer [C04]
 
 
ESR-16-12244, NCT03237377: Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Active, not recruiting
2
9
Canada, US
Durvalumab, [MEDI4736], Tremelimumab, [CP-675 206], Thoracic Radiation, lobectomy, Standard of care adjuvant chemotherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca
Non-Small Cell Lung Cancer
11/21
05/25
NCT02788773: Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Completed
2
52
Canada
Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Prostate Cancer
11/21
05/25
NCT03557918: Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Completed
2
26
US
Tremelimumab
Matthew Galsky, AstraZeneca
Urothelial Carcinoma
12/21
06/23
2021-002389-41: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit Capecitabin oder ohne Capecitabin in der ADJUvanten Situation bei Gallengangskrebs

Ongoing
2
40
Europe
Durvalumab, Tremelimumab, Capecitabine, Solution for infusion, Film-coated tablet, IMFINZI
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH
biliary tract cancer, biliary tract cancer, Diseases [C] - Cancer [C04]
 
 
SERPENTINE, NCT06680739: Single cEll pRofiling PErsistaNce To ImmuNothErapy

Recruiting
2
60
Europe
Durvalumab, Tremelimumab
Vall d'Hebron Institute of Oncology
Colorectal Cancer, Endometrial Cancer
09/25
12/25
IMMUCHEC, NCT03473574 / 2017-001538-25: Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Checkmark Presentation of data from IMMUCHEC trial for 1L biliary tract cancer at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from IMMUCHEC trial for 1L biliary tract cancer at ESMO 2022
Completed
2
128
Europe
Durvalumab, Gemcitabine, Cisplatin, Tremelimumab
AIO-Studien-gGmbH, AstraZeneca
Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable, Gallbladder Carcinoma Non-Resectable
03/22
03/22
PRODIGE 59 - DURIGAST, NCT03959293: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Active, not recruiting
2
107
Europe
Durvalumab, Tremelimumab, FOLFIRI Protocol
Federation Francophone de Cancerologie Digestive, AstraZeneca
Gastric Adenocarcinoma, Gastric Cancer
03/22
11/24
2021-004061-13: Durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors Tratamiento con durvalumab (MEDI4736) con o sin tremelimumab en tumores colorrectales y endometriales con MSS y MSI

Not yet recruiting
2
60
Europe
Tremelimumab, Durvalumab, Solution for infusion, Concentrate for solution for infusion
VHIO Vall d’Hebron Institute of Oncology, Astra Zeneca
MSS and MSI colorectal and endometrial tumors Tumores colorrectales y endometriales con MSS y MSI, MSS and MSI colorectal and endometrial tumors Tumores colorrectales y endometriales con MSS y MSI, Diseases [C] - Cancer [C04]
 
 
NCT02879162: Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Completed
2
140
Canada
Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Advanced Rare Tumours
06/21
01/25
2021-001907-33: A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with TheraSphere alone versus receiving radiation therapy with TheraSphere followed by immunotherapy (durvalumab and tremelimumab treatment) Estudio clínico para evaluar la seguridad y la eficacia de los sujetos con carcinoma hepatocelular (CHC) que reciben radioterapia con TheraSphere sola frente a los que reciben radioterapia con TheraSphere seguida de inmunoterapia (tratamiento con durvalumab y tremelimumab).

Not yet recruiting
2
150
Europe
Durvalumab, Tremelimumab, MEDI4736, MEDI1123, Concentrate for solution for infusion
Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation, Boston Scientific Corporation
hepatocellular carcinoma carcinoma hepatocelular, a cancer that starts in the liver un cáncer que comienza en el hígado, Diseases [C] - Cancer [C04]
 
 
AMBITION, NCT03699449: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer

Recruiting
2
104
RoW
olaparib+cediranib combination therapy, durvalumab + olaparib combination therapy, durvalumab + chemotherapy treatment, durvalumab + tremelimumab + chemotherapy treatment, durvalumab + tremelimumab + paclitaxel treatment, durvalumab +chemotherapy treatment
Yonsei University, AstraZeneca, Samsung Genomic Institute, Seoul National University Hospital, Samsung Medical Center, Korean Gynecologic Oncology Group
Platinum-resistant Recurrent Ovarian Cancer
09/22
09/22
TUOAD-RCC, NCT06584435: A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer Tumors

Recruiting
2
40
RoW
Tremelimumab
Tianjin Medical University Second Hospital
High-risk Renal Cell Carcinoma
12/24
03/25
IMMUNO-BIL, NCT03704480: Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

Active, not recruiting
2
106
Europe
Durvalumab, MEDI4736, Tremelimumab, CP-675
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Advanced Biliary Tract Carcinoma
07/22
12/24
ACTRN12618001742268: Non small cell lung cancer trial of durvalumab and tremelimumab in advanced epidermal growth factor receptor (EGFR) mutant disease.

Completed
2
100
 
University of Sydney, Astra Zeneca
EGFR mutant advanced non small cell lung cancer.
 
 
GUIDE2REPAIR, NCT04169841: Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Active, not recruiting
2
270
Europe
olaparib, durvalumab, tremelimumab
Centre Georges Francois Leclerc, AstraZeneca
Immunotherapy
08/27
08/27
2022-001201-48: Sequential or up-front triple treatment with of durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC) Sequenzielle oder frühzeitige dreifach-Therapie mit Durvalumab, Tremelimumab und Bevacizumab in Patienten mit nicht operierbarem Leberzellkarzinom (HCC)(MONTBLANC)

Not yet recruiting
2
70
Europe
IMFINZI, Tremelimumab, Aybintio, L01FG01, Concentrate for solution for infusion, IMFINZI, Aybintio
Klinikum der Ludwig-Maximillians-Universität München, Astra Zeneca
non-resectable hepatocellular carcinoma (HCC) nicht-resezierbares Hepatozelluläres Karzinom, non-resectable hepatocellular carcinoma (HCC) nicht-resezierbares Hepatozelluläres Karzinom, Diseases [C] - Cancer [C04]
 
 
CALYPSO, NCT02819596: MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

Hourglass Jan 2021 - Jun 2021 : Data from CALYPSO trial for metastatic renal cell carcinoma
Checkmark Data from CALYPSO study for RCC at ASCO-GU 2020
Feb 2020 - Feb 2020: Data from CALYPSO study for RCC at ASCO-GU 2020
Completed
2
69
Europe
Savolitinib, Volitinib, AZD6094, MEDI4736, Durvalumab, Tremelimumab
Queen Mary University of London, Vall d'Hebron Institute of Oncology, AstraZeneca
Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma
07/24
07/24
ACTRN12620000918921: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 7: Tremelimumab

Completed
2
24
 
The University of Sydney, Office for Health and Medical Research, Outsmarting Cancer Together - OMICO
cancer
 
 
2023-000138-13: Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanced cholangIOcarciNoma: an exploratory and translational study. CITATION study Studio multicentrico, interventistico, prospettico, farmacologico su chemio e immunoterapia neo- adiuvanti con durvalumab e tremelimumab nel trattamento preoperatorio del Colangiocarcinoma localmente avanzato: uno studio esploratorio traslazionale. STUDIO CITATION.

Not yet recruiting
2
38
Europe
Tremelimumab, Gemcitabina, Cisplatino, DURVALUMAB, [Tremelimumab], [Gemcitabina], [Cisplatino], [DURVALUMAB], Concentrate for solution for infusion, IMFINZI - 50 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 10 ML - 1 FLACONCINO
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A.
Locally advanced cholangiocarcinoma patients Pazienti affetti da CCA localmente avanzato, Locally advanced cholangiocarcinoma patients Pazienti affetti da CCA localmente avanzato, Diseases [C] - Cancer [C04]
 
 
NCT04221555: Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
68
RoW
Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab
Asan Medical Center
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
04/25
04/25
2021-004411-11: To investigate the efficacy and safety of neoadjuvant (preceding surgical removal) treatment with two cytostatic agents (gemcitabine, cisplatin) in combination with two monoclonal antibodies (durvalumab, tremelimumab) in patients with a specific type of malignant liver cancer. Untersuchung der Wirksamkeit und Sicherheit einer neoadjvanten (der operativen Entfernung vorgelagerten) Behandlung mit zwei Zytostatika (Gemcitabin, Cisplatin) in Kombination mit zwei monoklonalen Antikörpern (Durvalumab, Tremelimumab) bei Patienten mit einer bestimmten Form von bösartigem Leberkrebs

Not yet recruiting
2
31
Europe
Tremelimumab, Concentrate for solution for infusion, Powder for solution for infusion, IMFINZI
University Hospital Schleswig-Holstein, Campus Lübeck, AstraZeneca GmbH
Intrahepatic cholangiocarcinoma Intrahepatisches Cholangiokarzinom, Cancer that occurs in the parts of the bile ducts that are within the liver Krebs, der in den Teilen der Gallengänge auftritt, die sich innerhalb der Leber befinden, Diseases [C] - Cancer [C04]
 
 
ILLUMINATE, NCT03994393: Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Active, not recruiting
2
100
RoW
Tremelimumab, Durvalumab
University of Sydney, AstraZeneca, Australasian Lung Cancer Trials Group
EGFR Mutant Advanced Non Small Cell Lung Cancer
06/23
01/24
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial

Terminated
2
79
Europe
Durvalumab, MEDI4736, Tremelimumab
Grupo Espanol de Tumores Neuroendocrinos, MFAR
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
11/24
11/24
NCT04625699: Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Withdrawn
2
15
NA
Durvalumab, MEDI4736, IMFINZI, Tremelimumab, formerly CP-675,206
Catherine Shu
Nonsmall Cell Lung Cancer
07/23
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
brazikumab (AMG 139) / AstraZeneca
INTREPID OLE, NCT03961815 / 2019-001866-14: Open-label Extension Study of Brazikumab in Crohn's Disease

Jan 2024 - Dec 2024: Data from trial for Crohn's disease
Terminated
3
18
Europe, US, RoW
Brazikumab Induction Dose, Brazikumab Maintenance Dose
AstraZeneca
Crohn's Disease, IBD
09/23
09/23
INTREPID, NCT03759288 / 2018-004346-42: An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

Jan 2024 - Dec 2024: Data from INTREPID trial for Crohn’s disease
Checkmark Trial initiation for Crohn’s disease
Nov 2018 - Nov 2018: Trial initiation for Crohn’s disease
Terminated
2/3
89
Europe, Canada, US, RoW
Brazikumab low dose, Brazikumab high dose, Humira®, Placebo
AstraZeneca
Crohn's Disease, IBD
10/23
10/23
Expedition, NCT04718818: An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
225
Europe, Canada, US, RoW
Brazikumab, Vedolizumab, Placebo
AstraZeneca
Ulcerative Colitis
07/22
09/23
NCT04277546 / 2021-001644-10: Open-label Extension Study of Brazikumab in Ulcerative Colitis

Jan 2024 - Dec 2024: Data from trial for ulcerative colitis
Terminated
2
57
Europe, Japan, US, RoW
Brazikumab Maintenance Dose, Brazikumab Induction Dose
AstraZeneca
Ulcerative Colitis
10/23
10/23
NCT03616821 / 2018-001605-93: Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

Jan 2024 - Dec 2024: Data from EXPEDITION trial for ulcerative colitis
Checkmark Initiation of trial
Aug 2018 - Aug 2018: Initiation of trial
Terminated
2
242
Europe, Canada, Japan, US, RoW
Brazikumab, Placebo
AstraZeneca
Ulcerative Colitis, IBD
10/23
10/23
Xigduo (dapagliflozin and metformin extended-release) / AstraZeneca
NCT02911792: Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

Completed
4
72
US
Dapagliflozin, Farxiga, Metformin, Metformin-XR, Glipizide 5 MG
The University of Texas Health Science Center at San Antonio, AstraZeneca
Diabetes Mellitus, Type 2
07/23
07/23
NCT03710460: Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

Recruiting
4
33
RoW
Dapagliflozin, Forxiga, Dapagliflozin plus Metformin XR, XigDuo, Metformin XR
University of Guadalajara
Obesity
12/23
12/23
NCT06327815: Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Active, not recruiting
4
632
RoW
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, FDC Regimen of Dapagliflozin/Metformin XR, Dapagliflozin tablets and Metformin HCl extended-release tablets, Co-administered Dual Therapy
AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
04/25
06/25
NCT05601336: of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

Recruiting
3
200
RoW
Dapagliflozin 5 MG, [Farxiga], Metformin Hydrochloride 1000 MG, Glucophage 1000mg, Dapagliflozin/Metformin, Xigduo
Beni-Suef University
PCO
07/23
07/23
NCT06405178: Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Not yet recruiting
3
500
RoW
Metformin, Glucophage 1000, Dapagliflozin, Forxiga, Dapagliflozin/Metformin, Xigduo, Letrozole, femara
Beni-Suef University
Polycystic Ovary
12/24
12/24
NCT07026968: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Not yet recruiting
3
815
NA
Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
CSPC Ouyi Pharmaceutical Co., Ltd.
Type 2 Diabetes
10/26
11/26
EPIK-B4, NCT04899349: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Terminated
2
2
US, RoW
Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin
Novartis Pharmaceuticals
Breast Cancer
05/23
05/23
SOLDMiDiab02, NCT05477017: Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Not yet recruiting
N/A
800
Europe
SGLT2 inhibitor, Jardiance, Synjardy, Forxiga, Xigduo, Invokana, Vokanamet, Steglatro, Segluromet
University of Milan
Type2Diabetes
12/22
03/23
Imjudo (tremelimumab-actl) / AstraZeneca
2019-002767-98: A study of immunotherapy combined with regular treatment for liver cancer

Not yet recruiting
4
13
Europe
IMFINZI, Tremelimumab, Concentrate for solution for infusion, Solution for infusion, IMFINZI
University College Dublin, AstraZeneca
Patients with Hepatocellular Carcinoma, Liver Cancer, Diseases [C] - Cancer [C04]
 
 
ARCTIC, NCT02352948 / 2014-000338-46: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Not Appicable Jan 2018 - Jun 2018 : Acceptance of regulatory submission of durvalumab + tremelimumab based on ARCTIC trial for 3L NSCLC (P3 trial failed)
Not Appicable Jan 2018 - Jun 2018 : Acceptance of regulatory submission of durvalumab + tremelimumab based on ARCTIC trial for 3L NSCLC (P3 trial failed)
Not Appicable Jan 2018 - Jun 2018 : Regulatory submission of durvalumab + tremelimumab based on ARCTIC trial for 3L NSCLC (P3 trial failed)
Checkmark ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
Apr 2018 - Apr 2018: ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
More
Completed
3
597
Europe, Canada, Japan, US, RoW
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
AstraZeneca
Non - Small Cell Lung Cancer NSCLC
02/18
08/23
MYSTIC, NCT02453282 / 2015-001279-39: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Not Appicable Jan 2020 - Dec 2020 : Submission in China for durvalumab + tremelimumab combination in 1L NSCLC (based on MYSTIC trial) (P3 trial failed)
Checkmark From MYSTIC trial in 1L mNSCLC
Apr 2020 - Apr 2020: From MYSTIC trial in 1L mNSCLC
Checkmark Results for metastatic NSCLC [MYSTIC]
Dec 2018 - Dec 2018: Results for metastatic NSCLC [MYSTIC]
More
Active, not recruiting
3
1118
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
10/18
12/25
DANUBE , NCT02516241 / 2015-001633-24: Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Checkmark Withdrawal of advanced bladder cancer indication in the US
Feb 2021 - Feb 2021: Withdrawal of advanced bladder cancer indication in the US
Checkmark From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Sep 2020 - Sep 2020: From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Checkmark From DANUBE trial in combination with durvalumab vs chemo in Stage IV urothelial cancer
More
Active, not recruiting
3
1126
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine
AstraZeneca
Urothelial Cancer
01/20
12/25
CASPIAN, NCT03043872 / 2016-001203-23: Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer

Checkmark From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Sep 2021 - Sep 2021: From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Checkmark Approved in China for 1L ES-SCLC (based on CASPIAN Phase III trial)
Jul 2021 - Jul 2021: Approved in China for 1L ES-SCLC (based on CASPIAN Phase III trial)
Checkmark Approved in European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in 2L NSCLC
More
Active, not recruiting
3
987
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
01/20
12/25
NEPTUNE, NCT02542293 / 2015-002197-21: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC)

Not Appicable Jan 2020 - Dec 2020 : Submission for 1L NSCLC (based on NEPTUNE trial) in China (endpoint not met)
Checkmark From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Aug 2019 - Aug 2019: From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Active, not recruiting
3
953
Europe, Japan, US, RoW
Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
09/20
12/25
POSEIDON, NCT03164616 / 2017-000920-81: Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer ().

Checkmark Approved in combination with Imjudo + chemotherapy for treatment of unresectable, advanced/recurrent NSCLC based on POSEIDON trial
Dec 2022 - Dec 2022: Approved in combination with Imjudo + chemotherapy for treatment of unresectable, advanced/recurrent NSCLC based on POSEIDON trial
Checkmark Approved in EU in combination with tremelimumab 1L NSCLC cancer based on POSEIDON trial
Dec 2022 - Dec 2022: Approved in EU in combination with tremelimumab 1L NSCLC cancer based on POSEIDON trial
Checkmark Approved in US combination with tremelimumab for 1L NSCLC (based on POSEIDON trial)
More
Active, not recruiting
3
1186
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
AstraZeneca
Non Small Cell Lung Cancer NSCLC
03/21
11/27
HIMALAYA, NCT03298451 / 2016-005126-11: Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Hourglass Jan 2024 - Dec 2024 : Submission in China for 1L HCC (based on HIMALAYA trial)
Hourglass Jan 2023 - Dec 2023 : Regulatory decision in EU in combination with Imfinzi for 1L HCC (based on HIMALAYA trial)
Checkmark From HIMALAYA trial in combination with tremelimumab for 1L unresectable HCC at ASCO-GI 2023
Jan 2023 - Jan 2023: From HIMALAYA trial in combination with tremelimumab for 1L unresectable HCC at ASCO-GI 2023
Checkmark Approved in combination with Imjudo for unresectable HCC based on HIMALAYA trial
More
Active, not recruiting
3
1324
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)
AstraZeneca
Hepatocellular Carcinoma
08/21
08/26
2020-005452-38: Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse Cisplatin

Not yet recruiting
3
830
Europe
Durvalumab, Tremelimumab, Enfortumab vedotin, MEDI4736, EV, Concentrate for solution for infusion, Powder for solution for infusion, IMFINZI, Padcev
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Documented muscle-invasive urothelial carcinoma (UC) of the bladder incisplatin ineligible patients or Who Refuse Cisplatin, Cancer in thick muscle in the bladder wall, Diseases [C] - Cancer [C04]
 
 
NILE, NCT03682068 / 2018-001883-48: Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Hourglass Jul 2023 - Dec 2023 : Data from NILE trial in combination with tremelimumab for 1L bladder cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission (based on NILE trial) in combination with Imfinzi for urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission based on NILE trial in EU in combination with tremelimumab for 1L urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU in combination with Imfinzi for 1L urothelial cancer (based on NILE trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan in combination with tremelimumab for 1L urothelial cancer based on NILE trial
More
Active, not recruiting
3
1246
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine
AstraZeneca
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
06/25
06/25
NCT04585490: Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Recruiting
3
48
US
Durvalumab, Imfinzi, MEDI-4736, MEDI4736, Carboplatin, Carboplat, Carbosol, Carboplatino, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum, Pemetrexed, Alimta, MTA, LY231514, L-glutamic acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), Paclitaxel, Praxel, Cisplatin, platinum diamminodichloride, Abiplatin, Cismaplat, cis-platinum, Platinex, platinum, diaminedichloro-, cis- (8CI), AVENIO ctDNA Surveillance Kit, Tremelimumab, Imjudo, Tremelimumab-actl, Ticilimumab, CP-675, CP-675,206
Maximilian Diehn, AstraZeneca
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
04/26
04/28
RAMPART, NCT03288532 / 2017-002329-39: Renal Adjuvant MultiPle Arm Randomised Trial

Hourglass Oct 2023 - Dec 2023 : From RAMPART trial with or without in combination with tremelimumab
Recruiting
3
1750
Europe
Durvalumab, Tremelimumab
University College, London, AstraZeneca, Kidney Cancer UK, Cancer Research UK
Renal Cell Carcinoma
07/24
12/34
ADRIATIC, NCT03703297 / 2018-000867-10: Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Hourglass Jan 2024 - Dec 2024 : Regulatory submission for 1L SCLC
Hourglass Jan 2024 - Dec 2024 : Regulatory submission for SCLC
Jul 2023 - Dec 2023: Acceptance of regulatory submission in combination with tremelimumab for SCLC cancer (based on ADRIATIC trial)
Jan 2023 - Jun 2023: Data from ADRIATIC trial in combination with tremelimumab for stage I-III SCLC
Active, not recruiting
3
730
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Placebo
AstraZeneca
Small Cell Lung Cancer
03/26
03/26
TREMENDOUS, NCT05557838: Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Recruiting
3
210
RoW
Durvalumab, MEDI4736, Tremelimumab
AstraZeneca
Hepatocellular Carcinoma
03/25
03/25
ARTEMIDE-HCC01, NCT06921785: Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Recruiting
3
1220
Europe, Canada, Japan, US, RoW
Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab
AstraZeneca
Hepatocellular Carcinoma
03/29
03/30
SIERRA, NCT05883644: Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting
3
111
Europe, Japan, US, RoW
Durvalumab, Tremelimumab
AstraZeneca
Advanced Hepatocellular Carcinoma
09/25
03/26
DARTS, NCT07027436: Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

Not yet recruiting
3
30
Canada
Chemotherapy/Radiation, Group 1
Hamilton Health Sciences Corporation, McMaster University
Hepatocellular Carcinoma (HCC)
10/27
10/28
VOLGA, NCT04960709 / 2020-005452-38: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with tremelimumab and Padcev for MIBC (based on VOLGA trial)
Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Padcev and Imfinzi for MIBC (based on VOLGA trial)
Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi and tremelimumab for MIBC (based on VOLGA trial)
Jan 2024 - Dec 2024: Data from VOLGA trial in combination with tremelimumab and Padcev for MIBC
Active, not recruiting
3
712
Europe, Canada, Japan, US, RoW
Durvalumab, IMFINZI, MEDI4736, Tremelimumab, Enfortumab Vedotin, PADCEV, Radical Cystectomy
AstraZeneca, AstraZeneca AB
Muscle Invasive Bladder Cancer
07/25
09/28
EMERALD-3, NCT05301842 / 2021-003822-54: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with tremelimumab for HCC (based on EMERALD-3 trial)
Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi for HCC (based on EMERALD-3 trial)
Jan 2024 - Dec 2024: Data from EMERALD-3 trial in combination with tremelimumab for HCC
Active, not recruiting
3
760
Europe, Canada, Japan, US, RoW
Tremelimumab, MEDI1123, Durvalumab, MEDI4736, Transarterial Chemoembolization (TACE), DEB-TACE and cTACE, Lenvatinib, Lenvima
AstraZeneca
Hepatocellular Carcinoma
12/25
02/27
TRITON, NCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Recruiting
3
280
US
Durvalumab, MEDI4736 & IMFINZI®, Tremelimumab, IMJUDO®, Pemetrexed, Background Platinum-based Chemotherapy, Pembrolizumab, Carboplatin, Cisplatin
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/27
03/31
ALICE, NCT06904170: Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

Not yet recruiting
2/3
196
Europe
Durvalumab Plus Tremelimumab, HAIC (GEMOX)
UNICANCER, AstraZeneca
Hepatocellular Carcinoma
09/29
09/30
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Active, not recruiting
2/3
660
Europe, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
AbbVie
Hepatocellular Carcinoma
09/30
09/30
2015-001995-23: A SINGLE ARM, PHASE II CLINICAL STUDY OF TREMELIMUMAB COMBINED WITH THE ANTI-PD-L1 MEDI4736 MONOCLONAL ANTIBODY IN UNRESECTABLE MALIGNANT MESOTHELIOMA SUBJECTS: NIBIT-MESO-1 STUDY STUDIO CLINICO DI FASE II, A SINGOLO BRACCIO DI TRATTAMENTO CON LA COMBINAZIONE TREMELIMUMAB E L’ANTICORPO MONOCLONALE ANTI-PD-L1 MEDI4736 A IN SOGGETTII CON MESOTELIOMA MALIGNO NON RESECABILE

Not yet recruiting
2
40
Europe
Tremelimumab, MEDI4736, Solution for infusion
FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI, Astra Zeneca
UNRESECTABLE MALIGNANT MESOTHELIOMA MESOTELIOMA MALIGNO NON RESECABILE, UNRESECTABLE MALIGNANT MESOTHELIOMA MESOTELIOMA MALIGNO NON RESECABILE, Diseases [C] - Cancer [C04]
 
 
DETERMINE, NCT01843374 / 2012-003524-21: Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Checkmark From DETERMINE trial in 2nd-line malignant mesothelioma
Jul 2017 - Jul 2017: From DETERMINE trial in 2nd-line malignant mesothelioma
Hourglass Jul 2016 - Dec 2016 : Regulatory submission for mesothelioma
Checkmark Completion of enrollment in P2 trial for malignant mesothelioma
Nov 2016 - Nov 2016: Completion of enrollment in P2 trial for malignant mesothelioma
More
Active, not recruiting
2
571
Europe, Canada, US, RoW
Tremelimumab, Placebo
MedImmune LLC
Unresectable Pleural or Peritoneal Malignant Mesothelioma
01/16
04/25
2005-005660-86: A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal Adenocarcinoma

Ongoing
2
Europe
Ticilimumab, CP-675, 206,
Christie Hospital NHS Trust
Advanced Gastric/Oesophageal Adenocarcinoma
 
 
2016-001688-35: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors Studio in aperto, randomizzato, di fase 2 con l¿anticorpo anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, da solo o in combinazione con Tremelimumab, in pazienti con neoplasie germinali avanzate e ricadute alla chemioterapia

Ongoing
2
120
Europe
MEDI4736, Tremelimumab, MEDI4736, MEDI1123, Solution for infusion, Concentrate for solution for infusion
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Astra Zeneca
Advanced and relapsed germ cell tumors Neoplasie germinali in fase metastatica ricadute o in progressione dopo trattamento chemioterapico di seconda o terza linea., Germ cell Tumor Neoplasie germinali in fase metastatica ricadute o in progressione dopo trattamento chemioterapico di seconda o terza linea., Diseases [C] - Cancer [C04]
 
 
ESR-16-12012, NCT06446570: Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Completed
2
18
RoW
Durvalumab,Tremelimumab, Experimental group
Seoul National University Hospital, Korean Cancer Study Group
HNSCC, Head and Neck Neoplasms
02/19
06/21
NCT02527434 / 2015-002934-32: Study of Tremelimumab in Patients With Advanced Solid Tumors

Hourglass Nov 2018 - Dec 2018 : In urothelial bladder cancer, TNBC and pancreatic ductal adneocarcinoma
Completed
2
64
Europe, US, RoW
Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy
AstraZeneca
Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
02/18
03/23
2017-001664-37: A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC Studio randomizzato di fase 2 di confronto tra immunoterapia e chemioterapia nel trattamento del paziente anziano

Ongoing
2
240
Europe
CARBOPLATINO, Durvalumab, Tremelimumab, Gemcitabina, Pemetrexed, [CARBOPLATINO], [Durvalumab], [Tremelimumab], [Gemcitabina], [Pemetrexed], Concentrate for solution for infusion, Solution for infusion, CARBOPLATINO SANDOZ GMBH - 10MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 60ML, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 15 ML, ALIMTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A.
patients with advanced NSCLC pazienti con NSCLC avanzato, patients with advanced non-small cell lung cancer pazienti con tumore del polmone non a piccole cellule avanzato, Diseases [C] - Cancer [C04]
 
 
2017-004213-24: A RANDOMIZED TRIAL OF DURVALUMAB AND TREMELIMUMAB ¿ PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK, METASTATIC (STAGE IV) SQUAMOUS OR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) Studio randomizzato di Duravalumab e Tremelimumab ¿ Chemioterapia a base di platino in pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso

Not yet recruiting
2
300
Europe
Durvalumab, Tremelimumab, Gemcitabina, CARBOPLATINO, Pemetrexed, Durvalumab, Tremelimumab, Gemcitabina, CARBOPLATINO, Pemetrexed, Solution for infusion, Concentrate for solution for infusion, GEMCITABINA ACCORD HEALTHCARE - 1 G POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 50 ML, CARBOPLATINO AHCL - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 45 ML, ALIMTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, Canadian Cancer Trials Group (CCTG)
Patients with high-risk, metastatic (Stage IV) squamous or non-squamous NSCLC. Pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso., Patients with high-risk, metastatic (Stage IV) squamous or non-squamous NSCLC. Pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso., Diseases [C] - Cancer [C04]
 
 
2016-003175-22: Trial with immunotherapie for patients with locally advanced head and neck cancer Studie zur Immuntherapie bei Patienten mit lokal fortgeschrittenen Tumoren des Kopf-Hals Bereichs

Ongoing
2
120
Europe
Durvalumab, Tremelimumab, MEDI4736, Solution for infusion
Charite Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, AstraZeneca GmbH
NON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCC, locally advanced head and neck cancer Fortgeschrittene Kopf-Hals Tumoren, Diseases [C] - Cancer [C04]
 
 
2017-000577-36: DUTRELASCO trial (DUrvalumab with or without Tremelimumab in REsectable Locally Advanced Squamous cell Carcinoma of the Oral cavity)

Not yet recruiting
2
20
Europe
Tremelimumab, Durvalumab (Medi 4736), Medi 4736, Solution for infusion, Durvalumab (Medi 4736)
University Hospitals Leuven, University Hospitals Leuven, Astra Zeneca
resectable, locally advanced squamous cell carcinoma of the oral cavity, resectable, locally advanced squamous cell carcinoma of the oral cavity, Diseases [C] - Cancer [C04]
 
 
2017-003226-33: Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

Ongoing
2
120
Europe
Durvalumab, Tremelimumab, MEDI4736, MEDI1 123, Concentrate for solution for infusion
Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Jürgen Schüttler, Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg
Locally advanced head and neck squamous cell carcinoma (HNSCC), Head and neck cancer, Diseases [C] - Cancer [C04]
 
 
2017-003159-44: Durvalumab plus tremelimumab and radiotherapy for localized muscle invasivebladder cancer treatment Durvalumab más tremelimumab y radioterapia concomitante para el tratamiento del carcinoma de vejiga músculo-invasivo localizado

Ongoing
2
32
Europe
Durvalumab, Tremelimumab, MEDI4736, Tremelimumab, Solution for infusion
Spanish Oncology Genitourinary Group, AstraZeneca
Localized muscle invasive bladder cancer Carcinoma de vejiga músculo-invasivo localizado, Invasive bladder cancer Cáncer invasivo de vejiga, Diseases [C] - Cancer [C04]
 
 
ACTRN12617001468314: Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
2
80
 
NHMRC Clinical Trials Centre, Canadian Cancer Trials Group
Lung Cancer Metastatic
 
 
2018-002014-13: Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancer Évaluation de l'efficacité d'un traitement combiné immunothérapie + chimiothérapie pour traiter les patients atteints d'un cancer de l'estomac.

Not yet recruiting
2
94
Europe
MEDI4736, tremelimumab, MEDI4736, MEDI1123, Concentrate for solution for infusion
Fédération Francophone de Cancérologie Digestive, Astra Zeneca
Advanced gastric or gastro-oesophageal junction adenocarcinoma Adénocarcinome gastrique ou de la jonction oeso-gastrique avancé, Advanced gastric or gastro-oesophageal junction adenocarcinoma Adénocarcinome gastrique ou de la jonction oeso-gastrique avancé, Diseases [C] - Cancer [C04]
 
 
2018-003115-21: A phase II trIal for combination therapy with durvaLumab anD tremelimumAb in patients with metastatic solid tumors

Not yet recruiting
2
108
Europe
durvalumab, Tremelimumab, MEDI4736, Solution for infusion
Gustave Roussy, AstraZeneca
Metastatic colorectal adenocarcinoma (without microsatellite instability (not MSI)), triple negative breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma and human papilloma virus (HPV) negative head and neck squamous cell carcinoma with detection of ≥ 5 somatic mutations per megabase measured by whole exome sequencing in a tumor sample of the patient, Metastatic colorectal adenocarcinoma, breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma and HPV negative head and neck squamous cell carcinoma, Diseases [C] - Cancer [C04]
 
 
2017-003780-35: Phase II Study: Second line therapy in patients with non small cell lung cancer (NSCLC) with Durvalumab plus Tremelimumab after platinum based chemotherapie compared with platinum based chemotherapy alone Phase II Studie: Zweitlinientherapie in Patienten mit nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Durvalumab plus Tremelimumab nach Platinum-basierter Chemotherapie verglichen mit alleiniger Platinum-basierter Chemotherapie

Not yet recruiting
2
196
Europe
Durvalumab, Tremelimumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Gemcitabine, MEDI4736, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for infusion
AIO-Studien-gGmbH, AstraZeneca GmbH
Non-small cell lung cancer stage IV Nicht-kleinzelliges Bronchialkarzinom Stadium IV, Lungcancer Lungenkrebs, Diseases [C] - Cancer [C04]
 
 
2018-002971-17: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after Olaparib treatment Evaluation de l'efficacité d’une double immunothérapie par Durvalumab et Tremelimumab associée à un traitement par Olaparib chez des patients atteints d’un cancer solide porteurs d’une mutation d’un gène de la recombinaison homologue, en réponse ou stables après 8 semaines de traitement par Olaparib.

Not yet recruiting
2
270
Europe
OLAPARIB, DURVALUMAB, TREMELIMUMAB, AZD2281, MEDI4736, MEDI1123, Coated tablet, Concentrate for solution for infusion, Lynparza 100 mg film-coated Tablet
Centre Georges-François Leclerc, AstraZeneca, Centre Georges-François Leclerc
Patients with the following solid malignancy: • Metastatic breast cancer • Metastatic prostate cancer • Metastatic lung cancer • Metastatic head and neck • Metastatic endometrial cancer • Metastatic clear cell renal cancer • Metastatic pancreatic cancer • Metastatic ovarian cancer • Metastatic urothelial carcinoma Patients atteints d’une tumeur maligne parmi les suivantes : - Cancer du sein métastatique - Cancer de la prostate métastatique - Cancer du poumon métastatique - Cancer de l’endomètre métastatique - Cancer rénal à cellules claires métastatique - Cancer de la tête et du coup (ORL) métastatique - Cancer du pancréas métastatique - Cancer de l’ovaire localement avancé ou métastatique - Carcinome urothélial métastatique, Patient with the following metastatic solid malignancy of breast , prostate , lung , head and neck, endometrial, clear cell renal, pancreatic, ovarian or urothelial . Patient atteint d’une tumeur maligne métastatique du sein, de la prostate, du poumon, de l’endomètre, rénal à cellules claires, de la tête et du coup (ORL), du pancréas, de l’ovaire ou urothéliale., Diseases [C] - Cancer [C04]
 
 
2019-000308-13: Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virus

Not yet recruiting
2
180
Europe
Durvalumab, Cisplatin, MEDI4736, Concentrate for solution for infusion
European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Canadian Cancer Trials Group (CCTG), AstraZeneca
Oropharyngeal Squamous Cell Carcinoma, Cancer of the Head and Neck, Diseases [C] - Cancer [C04]
 
 
2018-004778-81: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Not yet recruiting
2
50
Europe
Durvalumab, Tremelimumab, Solution for infusion, IMFINZI
Institut für Klinische Krebsforschung IKF GmbH, AstraZeneca GmbH, BTG International Ltd.
Intrahepatic Biliary Tract Carcinoma, Intrahepatic Biliary Tract Cancer, Diseases [C] - Cancer [C04]
 
 
ACTRN12616001019493: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum: durvalumab plus tremelimumab

Completed
2
112
 
University of Sydney, Office for Health and Medical Research
Cancer
 
 
DUNE, NCT03095274 / 2016-002858-20: Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Completed
2
126
Europe
Durvalumab, MEDI4736, Tremelimumab, CP-675,206
Grupo Espanol de Tumores Neuroendocrinos
Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung
11/19
05/22
2018-002852-34: Durvalumab and Tremelimumab with microwave tumor ablation for unresectable locally advanced pancreatic cancer.

Not yet recruiting
2
20
Europe
Tremelimumab, Durvalumab (Medi4736), MEDI1123, MEDI4736, Solution for infusion, Durvalumab
UZLeuven, AstraZeneca
Unresectable Locally Advanced Non Metastatic Pancreatic Cancer, Pancreatic Cancer, Diseases [C] - Cancer [C04]
 
 
2018-001066-42: Durvalumab plus tremelimumab for progressive, refractory advanced thyroid carcinoma Durvalumab más tremelimumab para el carcinoma tiroideo avanzado, resistente al tratamiento y progresivo

Not yet recruiting
2
84
Europe
Durvalumab, Tremelimumab, MEDI4736, Tremelimumab, Solution for infusion, IMFINZI
Spanish Group of Neuroendocrine Tumors (GETNE), AstraZeneca
Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary,follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC).Advanced medullary thyroid carcinoma (MTC)Advanced anaplastic thyroid cancer (ATC) Carcinoma de tiroides diferenciado, avanzado, refractario al yodo radiactivo, incluyendo carcinoma tiroideo papilar, folicular, de células de Hürthle y poco diferenciado (CDT).Carcinoma medular de tiroides (CMT) avanzado.Cáncer anaplásico de tiroides (CAT) avanzado., Thyroid cancer Cáncer de tiroides, Diseases [C] - Cancer [C04]
 
 
CCTG BR34, NCT03057106 / ACTRN12617001468314: Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Active, not recruiting
2
301
Canada, RoW
Durvalumab, Tremelimumab, Platinum-Based Drug
Canadian Cancer Trials Group, AstraZeneca, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, National Health and Medical Research Council, Australia
Lung Cancer Metastatic
02/20
06/25
NCT03046862: Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Active, not recruiting
2
31
RoW
Durvalumab, MEDI4736, Tremelimumab, Gemcitabine, Cisplatin
Seoul National University Hospital
Biliary Tract Neoplasms
05/20
12/24
2018-003048-22: A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition Eine Phase II Studie zur Evaluation der Sicherheit und Wirksamkeit von Durvalumab in Kombination mit der standard neoadjuvanten Therapie sowie zur Evaluation von Durvalumab +/- Tremelimumab bei Patienten mit lokal fortgeschrittenem Adenokarzinom des Ösophagus und zusätzlich Evaluation von Biomarkern, die eine Ansprechen auf Immuncheckpoint Inhibitoren vorhersagen könnten

Not yet recruiting
2
56
Europe
Durvalumab, Tremelimumab, Solution for injection, Imfinzi®
Universität zu Köln, AstraZeneca Ab
locally advanced esophageal adenocarcinoma lokal fortgeschrittenes Adenokarzinom des Ösophagus, cancer of the esophagus lokal fortgeschrittenes Adenokarzinom der Speiseröhre, Diseases [C] - Cancer [C04]
 
 
BALTIC, NCT02937818 / 2016-001202-42: A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Checkmark Results in combination with tremelimumab for refractory/resistant ES-SCLC from BALTIC trial
Mar 2022 - Mar 2022: Results in combination with tremelimumab for refractory/resistant ES-SCLC from BALTIC trial
Completed
2
72
Europe, RoW
Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib
AstraZeneca
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
06/20
11/23
CCTG PA.7, NCT02879318: Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Completed
2
180
Canada
Gemcitabine, Nab-paclitaxel, Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Pancreatic Adenocarcinoma
08/20
03/25
2019-004597-26: A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT for intermediate stage HCC - IMMUWIN Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit Y-90 SIRT bei Patienten mit Leberzellkarzinom im Zwischenstadium - IMMUWIN

Not yet recruiting
2
54
Europe
Durvalumab, Tremelimumab, Solution for infusion, IMFINZI
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH
Intermediate stage hepatocellular carcinoma (HCC), Intermediate stage hepatocellular carcinoma (HCC), Diseases [C] - Cancer [C04]
 
 
SOGUG, NCT03702179 / 2017-003159-44: Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

Completed
2
32
Europe
Durvalumab, MEDI4736, Tremelimumab, Radiotherapy
Spanish Oncology Genito-Urinary Group, AstraZeneca, MFAR
Invasive Bladder Cancer
09/20
08/22
STUDY 22, NCT02519348 / 2015-001663-39: A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Checkmark From STUDY 22 trial in combination with tremelimumab at ASCO 2020
May 2020 - May 2020: From STUDY 22 trial in combination with tremelimumab at ASCO 2020
Active, not recruiting
2
433
Europe, Japan, US, RoW
Tremelimumab, Durvalumab, MEDI4736, Bevacizumab
MedImmune LLC
Hepatocellular Carcinoma
11/20
03/25
2020-003440-92: Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability. Studio con la combinazione di due farmaci immunoterapici come terapia prima della chirurgia o come terapia definitiva in pazienti con tumore gastrico o della giunzione gastro-esofagea operabile con instabilità dei microsatelliti.

Not yet recruiting
2
31
Europe
Durvalumab, Tremelimumab, [MEDI4736], [MEDI1123], Concentrate for solution for infusion
G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST, Fondazione GONO, AstraZeneca S.p.A.
The disease under clinical investigation is represented by resectable gastric or gastroesophageal junction (Siewert II-III) adenocarcinoma staged as cT = 2, any cN, or any cT, cN1-3 (TNM classification 8th edition), without distant metastases (cM0).The study requires central confirmation of tumor molecular status of microsatellite instability and dMMR by both immunohistochemistry and multiplex polymerase chain reaction, and EBV-negative status by silver-in situ hybridization. La malattia oggetto di studio clinico è costituita dall'adenocarcinoma gastrico o della giunzione gastroesofagea (Siewert II-III) resecabile, stadiato clinicamente secondo la classificazione TNM (8° edizione) come cT = 2, ogni cN, oppure ogni cT, cN1-3, senza evidenza di metastasi a distanza (cM0). E' necessaria conferma centralizzata di instabilità microsatellitare mediante immunoistochimica e reazione polimerasica a catena, e status EBV-negativo mediante ibridizzazione in situ argentica., Cancer in the stomach or in the junction between the stomach and the oesophagus, without metastases in other organs and surgically resectable, with microsatellite instability and no EBV infection. Tumore nello stomaco o nella giunzione tra stomaco ed esofago, senza metastasi in altri organi e asportabile chirurgicamente, con instabilità dei microsatelliti e assenza di infezione da EBV., Diseases [C] - Cancer [C04]
 
 
16-C-0135, NCT02821754: A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Completed
2
54
US
Durvalumab, Imfinzi, Tremelimumab, Ticilimumab, Trans-arterial Catheter Chemoembolization (TACE), TACE, Radiofrequency Ablation (RFA), RFA, Cryoablation, Cryosurgery
National Cancer Institute (NCI)
Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
02/21
12/22
DUTRENEO, NCT03472274 / 2017-002246-68: Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients

Completed
2
101
Europe
Durvalumab, Tremelimumab, Cisplatin-based neoadjuvant chemotherapy, Standard of care (SoC)
Fundacion CRIS de Investigación para Vencer el Cáncer, AstraZeneca, Apices Soluciones S.L.
Bladder Cancer
04/21
04/23
NCT03377400: Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Active, not recruiting
2
40
RoW
Durvalumab, tremelimumab, 5FU, Cisplatin
Samsung Medical Center
Esophageal Squamous Cell Carcinoma
06/21
12/21
NCT03450967: Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Active, not recruiting
2
31
RoW
Durvalumab Plus Tremelimumab
Samsung Medical Center
Head and Neck Squamous Cell Carcinoma
06/21
03/22
ACTRN12618000109202: A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers “iPRIME”.

Completed
2
75
 
Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Ovarian cancer, Fallopian tube cancer, Peritoneal cancer
 
 
NRG-GY021, NCT04034927: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Active, not recruiting
2
61
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Ticilimumab, Tremelimumab-actl
National Cancer Institute (NCI), NRG Oncology
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
07/21
02/26
NCT02953457: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Completed
2
40
US
Durvalumab, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Olaparib, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
Roswell Park Cancer Institute, AstraZeneca
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
09/21
08/24
CheckRad-CD8, NCT03426657: Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

Completed
2
120
Europe
Durvalumab + Tremelimumab + RT
University of Erlangen-Nürnberg Medical School
Locally Advanced Head and Neck Squamous Cell Carcinoma
09/21
02/24
2020-003925-42: Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer

Not yet recruiting
2
84
Europe
Tremelimumab, Durvalumab, TheraSphere, Solution for infusion, Implant, TheraSphere
Clinics of Munich University LMU, Astra Zeneca, Boston Scientific
Patients with hepatocellular cancer, not amenable to curative surgical or ablation treatment., tumor of the liver which cannot be removed by surgery or other ablation techniques, Diseases [C] - Cancer [C04]
 
 
ESR-16-12244, NCT03237377: Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Active, not recruiting
2
9
Canada, US
Durvalumab, [MEDI4736], Tremelimumab, [CP-675 206], Thoracic Radiation, lobectomy, Standard of care adjuvant chemotherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca
Non-Small Cell Lung Cancer
11/21
05/25
NCT02788773: Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Completed
2
52
Canada
Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Prostate Cancer
11/21
05/25
NCT03557918: Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Completed
2
26
US
Tremelimumab
Matthew Galsky, AstraZeneca
Urothelial Carcinoma
12/21
06/23
2021-002389-41: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit Capecitabin oder ohne Capecitabin in der ADJUvanten Situation bei Gallengangskrebs

Ongoing
2
40
Europe
Durvalumab, Tremelimumab, Capecitabine, Solution for infusion, Film-coated tablet, IMFINZI
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH
biliary tract cancer, biliary tract cancer, Diseases [C] - Cancer [C04]
 
 
SERPENTINE, NCT06680739: Single cEll pRofiling PErsistaNce To ImmuNothErapy

Recruiting
2
60
Europe
Durvalumab, Tremelimumab
Vall d'Hebron Institute of Oncology
Colorectal Cancer, Endometrial Cancer
09/25
12/25
IMMUCHEC, NCT03473574 / 2017-001538-25: Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Checkmark Presentation of data from IMMUCHEC trial for 1L biliary tract cancer at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from IMMUCHEC trial for 1L biliary tract cancer at ESMO 2022
Completed
2
128
Europe
Durvalumab, Gemcitabine, Cisplatin, Tremelimumab
AIO-Studien-gGmbH, AstraZeneca
Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable, Gallbladder Carcinoma Non-Resectable
03/22
03/22
PRODIGE 59 - DURIGAST, NCT03959293: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Active, not recruiting
2
107
Europe
Durvalumab, Tremelimumab, FOLFIRI Protocol
Federation Francophone de Cancerologie Digestive, AstraZeneca
Gastric Adenocarcinoma, Gastric Cancer
03/22
11/24
2021-004061-13: Durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors Tratamiento con durvalumab (MEDI4736) con o sin tremelimumab en tumores colorrectales y endometriales con MSS y MSI

Not yet recruiting
2
60
Europe
Tremelimumab, Durvalumab, Solution for infusion, Concentrate for solution for infusion
VHIO Vall d’Hebron Institute of Oncology, Astra Zeneca
MSS and MSI colorectal and endometrial tumors Tumores colorrectales y endometriales con MSS y MSI, MSS and MSI colorectal and endometrial tumors Tumores colorrectales y endometriales con MSS y MSI, Diseases [C] - Cancer [C04]
 
 
NCT02879162: Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Completed
2
140
Canada
Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Advanced Rare Tumours
06/21
01/25
2021-001907-33: A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with TheraSphere alone versus receiving radiation therapy with TheraSphere followed by immunotherapy (durvalumab and tremelimumab treatment) Estudio clínico para evaluar la seguridad y la eficacia de los sujetos con carcinoma hepatocelular (CHC) que reciben radioterapia con TheraSphere sola frente a los que reciben radioterapia con TheraSphere seguida de inmunoterapia (tratamiento con durvalumab y tremelimumab).

Not yet recruiting
2
150
Europe
Durvalumab, Tremelimumab, MEDI4736, MEDI1123, Concentrate for solution for infusion
Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation, Boston Scientific Corporation
hepatocellular carcinoma carcinoma hepatocelular, a cancer that starts in the liver un cáncer que comienza en el hígado, Diseases [C] - Cancer [C04]
 
 
AMBITION, NCT03699449: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer

Recruiting
2
104
RoW
olaparib+cediranib combination therapy, durvalumab + olaparib combination therapy, durvalumab + chemotherapy treatment, durvalumab + tremelimumab + chemotherapy treatment, durvalumab + tremelimumab + paclitaxel treatment, durvalumab +chemotherapy treatment
Yonsei University, AstraZeneca, Samsung Genomic Institute, Seoul National University Hospital, Samsung Medical Center, Korean Gynecologic Oncology Group
Platinum-resistant Recurrent Ovarian Cancer
09/22
09/22
TUOAD-RCC, NCT06584435: A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer Tumors

Recruiting
2
40
RoW
Tremelimumab
Tianjin Medical University Second Hospital
High-risk Renal Cell Carcinoma
12/24
03/25
IMMUNO-BIL, NCT03704480: Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

Active, not recruiting
2
106
Europe
Durvalumab, MEDI4736, Tremelimumab, CP-675
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Advanced Biliary Tract Carcinoma
07/22
12/24
ACTRN12618001742268: Non small cell lung cancer trial of durvalumab and tremelimumab in advanced epidermal growth factor receptor (EGFR) mutant disease.

Completed
2
100
 
University of Sydney, Astra Zeneca
EGFR mutant advanced non small cell lung cancer.
 
 
GUIDE2REPAIR, NCT04169841: Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Active, not recruiting
2
270
Europe
olaparib, durvalumab, tremelimumab
Centre Georges Francois Leclerc, AstraZeneca
Immunotherapy
08/27
08/27
2022-001201-48: Sequential or up-front triple treatment with of durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC) Sequenzielle oder frühzeitige dreifach-Therapie mit Durvalumab, Tremelimumab und Bevacizumab in Patienten mit nicht operierbarem Leberzellkarzinom (HCC)(MONTBLANC)

Not yet recruiting
2
70
Europe
IMFINZI, Tremelimumab, Aybintio, L01FG01, Concentrate for solution for infusion, IMFINZI, Aybintio
Klinikum der Ludwig-Maximillians-Universität München, Astra Zeneca
non-resectable hepatocellular carcinoma (HCC) nicht-resezierbares Hepatozelluläres Karzinom, non-resectable hepatocellular carcinoma (HCC) nicht-resezierbares Hepatozelluläres Karzinom, Diseases [C] - Cancer [C04]
 
 
CALYPSO, NCT02819596: MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

Hourglass Jan 2021 - Jun 2021 : Data from CALYPSO trial for metastatic renal cell carcinoma
Checkmark Data from CALYPSO study for RCC at ASCO-GU 2020
Feb 2020 - Feb 2020: Data from CALYPSO study for RCC at ASCO-GU 2020
Completed
2
69
Europe
Savolitinib, Volitinib, AZD6094, MEDI4736, Durvalumab, Tremelimumab
Queen Mary University of London, Vall d'Hebron Institute of Oncology, AstraZeneca
Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma
07/24
07/24
ACTRN12620000918921: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 7: Tremelimumab

Completed
2
24
 
The University of Sydney, Office for Health and Medical Research, Outsmarting Cancer Together - OMICO
cancer
 
 
2023-000138-13: Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanced cholangIOcarciNoma: an exploratory and translational study. CITATION study Studio multicentrico, interventistico, prospettico, farmacologico su chemio e immunoterapia neo- adiuvanti con durvalumab e tremelimumab nel trattamento preoperatorio del Colangiocarcinoma localmente avanzato: uno studio esploratorio traslazionale. STUDIO CITATION.

Not yet recruiting
2
38
Europe
Tremelimumab, Gemcitabina, Cisplatino, DURVALUMAB, [Tremelimumab], [Gemcitabina], [Cisplatino], [DURVALUMAB], Concentrate for solution for infusion, IMFINZI - 50 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 10 ML - 1 FLACONCINO
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A.
Locally advanced cholangiocarcinoma patients Pazienti affetti da CCA localmente avanzato, Locally advanced cholangiocarcinoma patients Pazienti affetti da CCA localmente avanzato, Diseases [C] - Cancer [C04]
 
 
NCT04221555: Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
68
RoW
Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab
Asan Medical Center
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
04/25
04/25
2021-004411-11: To investigate the efficacy and safety of neoadjuvant (preceding surgical removal) treatment with two cytostatic agents (gemcitabine, cisplatin) in combination with two monoclonal antibodies (durvalumab, tremelimumab) in patients with a specific type of malignant liver cancer. Untersuchung der Wirksamkeit und Sicherheit einer neoadjvanten (der operativen Entfernung vorgelagerten) Behandlung mit zwei Zytostatika (Gemcitabin, Cisplatin) in Kombination mit zwei monoklonalen Antikörpern (Durvalumab, Tremelimumab) bei Patienten mit einer bestimmten Form von bösartigem Leberkrebs

Not yet recruiting
2
31
Europe
Tremelimumab, Concentrate for solution for infusion, Powder for solution for infusion, IMFINZI
University Hospital Schleswig-Holstein, Campus Lübeck, AstraZeneca GmbH
Intrahepatic cholangiocarcinoma Intrahepatisches Cholangiokarzinom, Cancer that occurs in the parts of the bile ducts that are within the liver Krebs, der in den Teilen der Gallengänge auftritt, die sich innerhalb der Leber befinden, Diseases [C] - Cancer [C04]
 
 
ILLUMINATE, NCT03994393: Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Active, not recruiting
2
100
RoW
Tremelimumab, Durvalumab
University of Sydney, AstraZeneca, Australasian Lung Cancer Trials Group
EGFR Mutant Advanced Non Small Cell Lung Cancer
06/23
01/24
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial

Terminated
2
79
Europe
Durvalumab, MEDI4736, Tremelimumab
Grupo Espanol de Tumores Neuroendocrinos, MFAR
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
11/24
11/24
NCT04625699: Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Withdrawn
2
15
NA
Durvalumab, MEDI4736, IMFINZI, Tremelimumab, formerly CP-675,206
Catherine Shu
Nonsmall Cell Lung Cancer
07/23
12/23
 

Download Options